Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07090486 · ClinicalTrials.gov registry record
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 14,000
- Enrollment target
NCT07090486: Completed study, sponsored by Pfizer.
NCT07090486 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 14,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07090486 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 14,000 participants
- Enrollment target
Study Summary
This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom. This study will look at the change in Post Covid Conditions measured by the number of outpatients, Emergency department, urgent care and inpatient visits before and after COVID-19 between those who did and did not receive Paxlovid. In addition, changes in frailty post-acute infection will be evaluated, in a separate analysis. It is hypothesized that individuals with COVID-19 who received Paxlovid will have a smaller post-COVID-19 increase (vs pre-COVID) in PCC healthcare utilization (i.e., cardiopulmonary) in comparison to patients with COVID-19 who did not receive Paxlovid.
Interventions
- DRUG nirmatrelvir-ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,000 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2025-04-15 |
What the finished NCT07090486 record still lists
NCT07090486 is an observational study that tracks outcomes without assigning an intervention. Its 14,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which nirmatrelvir-ritonavir is the first listed.
NCT07090486 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07090486 about?
NCT07090486 is a clinical study titled "A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.". This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom. This study will look at the change in Post Covid Conditions measured by the number of outpatients, Emergency departme...
What is the current status of trial NCT07090486?
This trial is currently completed. The enrollment target is 14,000 participants. The study started on 2025-04-15. Estimated completion is 2025-04-15.
What interventions are being tested in trial NCT07090486?
The interventions under investigation include: nirmatrelvir-ritonavir (DRUG).
Who is sponsoring clinical trial NCT07090486?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI